WO2013160882A1 - Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method. - Google Patents
Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method. Download PDFInfo
- Publication number
- WO2013160882A1 WO2013160882A1 PCT/IB2013/053321 IB2013053321W WO2013160882A1 WO 2013160882 A1 WO2013160882 A1 WO 2013160882A1 IB 2013053321 W IB2013053321 W IB 2013053321W WO 2013160882 A1 WO2013160882 A1 WO 2013160882A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- expression
- cells
- include measuring
- binding
- respiratory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/14—Disorders of ear, nose or throat
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to a method for identifying agents capable of inducing respiratory sensitization and arrays and analytical kits for use in such methods.
- This hypersensitivity reaction is immediate, with clinical characteristics occurring within minutes to hours after xenobiotic exposure, and can include wheezing, breathlessness, tightness in the chest, bronchoconstriction, and/or nasal congestion. In extreme cases the reaction can elicit hypotension and life-threatening anaphylaxis.
- respiratory allergy is most frequently induced by environmental proteins including pollen, dust mite excreta and animal dander.
- respiratory allergy can be mediated by industrial compounds including high molecular weight (HMW) compounds, such as protein detergents, and low molecular weight (LMW) chemicals. Due to their small size, LMW chemical allergens act as haptens which first react with proteins to create a complex that is then able to initiate an immune response.
- HMW high molecular weight
- LMW low molecular weight
- ACD is an example of a delayed-type hypersensitivity reaction resulting from cell-mediated immune responses (Janeway et al., 1997 supra).
- ACD is one of the most common occupational diseases with a number of compounds being implicated as causative agents, therefore, proactive identification and characterization of these compounds are also of considerable importance (Saary, J., Qureshi, R., Palda, V., DeKoven, J., Pratt, M., Skotnicki-Grant, S., Holness, L, 2005. A systematic review of contact dermatitis treatment and prevention. J. Am. Acad. Dermatol. 53, 845).
- the development of hypersensitivity resulting in respiratory allergy or ACD consists of two distinct stages. The first is sensitization, which involves the development of an immune status, while the second is elicitation, which results in the clinical manifestation of allergy (Briatico-Vangosa, G., Braun, C.L., Cookman, G., Hofmann, T., Kimber, I., Loveless, S.E., Morrow, T., Pauluhn, J., Sorensen, T., Niessen, H.J., 1994. Respiratory allergy: hazard identification and risk assessment. Fundam. Appl. Toxicol. 23, 145-158).
- the nature and severity of the allergic reaction are dependent upon a number of factors including the genetic background of the individual, the characteristics of the allergen, as well as the route, duration and intensity of the exposure during both the sensitization and elicitation stages (Arts, J.H., Kuper, C, 2003. Approaches to induce and elicit respiratory allergy: impact of route and intensity of exposure. Toxicol. Lett. 140-141 , 213-222; Arts, J.H., Mommers, C, de Heer, C, 2006. Dose-response relationships and threshold levels in skin and respiratory allergy. Crit. Rev. Toxicol. 36, 219-251). Despite some general similarities, there are important mechanistic differences in the currently understood etiology of respiratory allergy and ACD.
- respiratory allergy is classified as a type I hypersensitivity reaction involving IgE while ACD is a type IV hypersensitivity reaction which is mediated by T cells (Janeway et al., 1997 supra).
- Th T helper
- Th1 and Th2 cells T helper cells
- Th2 cytokines In addition to promoting IgE production, Th2 cytokines also promote the growth and differentiation of other cells involved in respiratory allergy including mast cells and eosinophils (reviewed in Kimber, I., 1996. Chemical-induced hypersensitivity. In: Smialowicz, R.J., Holsapple, MP. (Eds.), Experimental Immunotoxicology. CRC Press, New York, pp. 391-417). Upon repeated exposure to allergenic compounds and the elicitation of respiratory allergy, extensive airway remodeling, mucus accumulation and chronic inflammatory responses may develop which contribute to the development of an asthmatic condition. In contrast, the development of contact sensitization and ACD has been primarily associated with the induction of a Th1 population of T lymphocytes.
- IFN- ⁇ interferon-gamma
- TNF- ⁇ tumor necrosis factor- ⁇
- the sensitization response is associated with the generation of memory T cells which are activated upon subsequent encounter with the antigen resulting in the hypersensitivity response.
- This reaction involves the activation of keratinocytes and the release of proinflammatory cytokines to recruit non-antigen specific T cells and monocytes to the site of contact which results in an acute inflammatory response.
- IFN- ⁇ produced by Th1 cells also antagonizes Th2 cell responses and the production of IgE, while IL-4 produced by Th2 cells antagonizes the development of Th1 cells.
- IFN- ⁇ has been found to inhibit mast cell function in respiratory allergy, while IL-4 depresses the elicitation stage of ACD (reviewed in Kimber, 1996 supra). Therefore, not only do the cytokines of each Th cell type promote the growth and differentiation of their lineage and the subsequent hypersensitivity response, they also antagonize the proliferation of the other cell population as a means of further directing the immune response.
- Respiratory allergy is a type I hypersensitivity reaction of the upper and lower respiratory tract to xenobiotic proteins or chemicals, with clinical symptoms typically including wheezing, breathlessness, bronchochonstriction and asthmatic attacks (Boverhof DR, Billington R, Gollapudi BB, Hotchkiss JA, Krieger SM, et al. (2008) Respiratory sensitization and allergy: current research approaches and needs. Toxicol AppI Pharmacol 226: 1-13).
- respiratory allergy is associated with the induction of Th2 cells and increased IgE production by B cells.
- the type I hypersensitivity reaction is classically triggered by protein allergens, while low- molecular weight compounds have a propensity to induce Allergic Contact Dermatitis (ACD), a type IV hypersensitivity reaction that has primarily been associated with the induction of Th1 and CD8 + effector cells.
- ACD Allergic Contact Dermatitis
- a number of chemicals such as diisocyanates (Zammit-Tabona M, Sherkin M, Kijek K, Chan H, Chan-Yeung M (1983) Asthma caused by diphenylmethane diisocyanate in foundry workers. Clinical, bronchial provocation, and immunologic studies.
- the REACH (Registration, Evaluation, and Authorisation of Chemicals) regulation requires that all new and existing chemicals within the European Union, involving approximately 30000 chemicals, should be tested for hazardous effects (Johansson H, Lindstedt , Albrekt AS, Borrebaeck CA: A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics 2011 , 12:399). As the identification of potential sensitizers currently requires animal testing, the REACH legislation will have a huge impact on the number of animals needed for testing.
- the main in vivo assay designed for this purpose is the mouse IgE test (Dearman RJ, Basketter DA, Kimber I (1992) Variable effects of chemical allergens on serum IgE concentration in mice. Preliminary evaluation of a novel approach to the identification of respiratory sensitizers. J Appl Toxicol 12: 317- 323; Dearman RJ, Skinner RA, Humphreys NE, Kimber I (2003) Methods for the identification of chemical respiratory allergens in rodents: comparisons of cytokine profiling with induced changes in serum IgE. J Appl Toxicol 23: 199-207). Although showing promising initial results, interlaboratory reproducibility was not sufficient to formally validate this assay, and it is today not routinely used.
- DCs Dendritic cells
- a cell line with DC characteristics would be advantageous, as it constitutes a stable, reproducible and unlimited supply of cells.
- differentiated myelomonocytic MUTZ-3 cells are the preferred candidate (Masterson, A. J., C. C. Sombroek, T. D. De GruijI, Y. M. Graus, H. J. van der Vliet, S. M. Lougheed, A. J. van den Eertwegh, H. M. Pinedo, and R. J. Scheper. 2002.
- MUTZ-3 a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood 100:701-703.).
- MUTZ-3 is as an unlimited source of CD34 + DC progenitors and it can acquire, upon cytokine stimulation, phenotypes similar to immature DCs or Langerhans-like DCs (Santegoets, S. J., M. W. Schreurs, A. J. Masterson, Y. P. Liu, S. Goletz, H. Baumeister, E. W. Kueter, S. M. Lougheed, A. J. van den Eertwegh, R. J. Scheper, E. Hooijberg, and T. D.
- MUTZ-3 a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood 100:701-703.).
- MUTZ- 3 also displays a mature transcriptional and phenotypic profile upon stimulation with inflammatory mediators (Larsson K, Lindstedt M, and Borrebaeck CAK. Functional and transcriptional profiling of MUTZ-3. A myeloid cell line acting as a model for dendritic cells. Immunology. 2006 Feb; 117(2): 156-66.)
- the present inventors have developed a novel test principle for prediction of respiratory sensitizers. It has surprisingly been found that respiratory sensitizers can be accurately identified/predicted using DC progenitor cells, such as MUTZ-3 cells, without further differentiation in a process whereby the cells are stimulated with a panel of sensitizing chemicals, non-sensitizing chemicals, and/or other controls (e.g. vehicle controls comprising diluent only, such as DMSO and/or distilled water). This was found to substantially simplify and improve the reproducibility of the procedure.
- DC progenitor cells such as MUTZ-3 cells
- a first aspect of the present invention provides a method for identifying agents capable of inducing respiratory sensitization in a mammal comprising or consisting of the steps of: a) exposing a population of dendritic cells or a population of dendritic-like cells to a test agent; and
- the expression in the cells of the one or more biomarkers measured in step (b) is indicative of the respiratory sensitizing effect of the test agent.
- agents capable of inducing respiratory sensitization we mean any agent capable of inducing and triggering a Type I immediate hypersensitivity reaction in the respiratory tract of a mammal.
- the mammal is a human.
- the Type I immediate hypersensitivity reaction is DC-mediated and/or involves the differentiation of T cells into Th2 cells.
- the Type I immediate hypersensitivity reaction results in humoral immunity and/or respiratory allergy.
- the conducting zone of the mammalian lung contains the trachea, the bronchi, the bronchioles, and the terminal bronchioles.
- the respiratory zone contains the respiratory bronchioles, the alveolar ducts, and the alveoli.
- the conducting zone is made up of airways, has no gas exchange with the blood, and is reinforced with cartilage in order to hold open the airways.
- the conducting zone humidifies inhaled air and warms it to 37 °C (99 °F). It also cleanses the air by removing particles via cilia located on the walls of all the passageways.
- the respiratory zone is the site of gas exchange with blood.
- the "agents capable of inducing sensitization of mammalian skin” is an agent capable of inducing and triggering a Type I immediate hypersensitivity reaction at a site of lung epithelium in a mammal.
- the site of lung epithelium is in the respiratory zone of the lung, but may alternatively or additionally be in the conductive zone of the lung.
- the mammal may be any domestic or farm animal.
- the mammal is a rat, mouse, guinea pig, cat, dog, horse or a primate.
- the mammal is human.
- DCs Dendritic cells
- Their main function is to process antigen material and present it on the surface to other cells of the immune system (i.e., they function as antigen-presenting cells), bridging the innate and adaptive immune systems.
- Dendritic cells are present in tissues in contact with the external environment, such as the skin (where there is a specialized dendritic cell type called Langerhans cells) and the inner lining of the nose, lungs, stomach and intestines. They can also be found in an immature state in the blood. Once activated, they migrate to the lymph nodes where they interact with T cells and B cells to initiate and shape the adaptive immune response. At certain development stages they grow branched projections, the dendrites. While similar in appearance, these are distinct structures from the dendrites of neurons. Immature dendritic cells are also called veiled cells, as they possess large cytoplasmic 'veils' rather than dendrites.
- dendritic-like cells we mean non-dendritic cells that exhibit functional and phenotypic characteristics specific to dendritic cells such as morphological characteristics, expression of costimulatory molecules and MHC class II molecules, and the ability to pinocytose macromolecules and to activate resting T cells.
- the dendritic-like cells are CD34 + dendritic cell progenitors.
- the CD34 + dendritic cell progenitors can acquire, upon cytokine stimulation, the phenotypes of presenting antigens through CD1d, MHC class I and II, induce specific T-cell proliferation, and/or displaying a mature transcriptional and phenotypic profile upon stimulation with inflammatory mediators (i.e. similar phenotypes to immature dendritic cells or Langerhans-like dendritic cells).
- Dendritic cells may be recognized by function, by phenotype and/or by gene expression pattern, particularly by cell surface phenotype. These cells are characterized by their distinctive morphology, high levels of surface MHC-class II expression and ability to present antigen to CD4+ and/or CD8+ T cells, particularly to naive T cells (Steinman et al. (1991) Ann. Rev. Immunol. 9: 271).
- the cell surface of dendritic cells is unusual, with characteristic veil-like projections, and is characterized by expression of the cell surface markers CD11c and MHC class II. Most DCs are negative for markers of other leukocyte lineages, including T cells, B cells, monocytes/macrophages, and granulocytes.
- Subpopulations of dendritic cells may also express additional markers including 33D1 , CCR1 , CCR2, CCR4, CCR5, CCR6, CCR7, CD1a-d, CD4, CD5, CD8alpha, CD9, CD11b, CD24, CD40, CD48, CD54, CD58, CD80, CD83, CD86, CD91 , CD117, CD123 (IL3Ra), CD134, CD137, CD150, CD153, CD162, CXCR1 , CXCR2, CXCR4, DCIR, DC- LAMP, DC-SIGN, DEC205, E-cadherin, Langerin, Mannose receptor, MARCO, TLR2, TLR3 TLR4, TLR5, TLR6, TLR9, and several lectins.
- additional markers including 33D1 , CCR1 , CCR2, CCR4, CCR5, CCR6, CCR7, CD1a-d, CD4, CD5, CD8alpha, CD9, CD11b, CD24, CD40, CD
- the patterns of expression of these cell surface markers may vary along with the maturity of the dendritic cells, their tissue of origin, and/or their species of origin.
- Immature dendritic cells express low levels of MHC class II, but are capable of endocytosing antigenic proteins and processing them for presentation in a complex with MHC class II molecules.
- Activated dendritic cells express high levels of MHC class 11 , ICAM-1 and CD86, and are capable of stimulating the proliferation of naive allogeneic T cells, e. g. in a mixed leukocyte reaction (MLR).
- MLR mixed leukocyte reaction
- dendritic cells or dendritic-like cells may be identified by any convenient assay for determination of antigen presentation.
- assays may include testing the ability to stimulate antigen- primed and/or naive T cells by presentation of a test antigen, followed by determination of T cell proliferation, release of IL-2, and the like.
- expression we mean the level or amount of a gene product such as mRNA or protein.
- Preferred methods for detection and/or measurement of protein include Western blot, North-Western blot, immunosorbent assays (ELISA), antibody microarray, tissue microarray (TMA), immunoprecipitation, in situ hybridisation and other immunohistochemistry techniques, radioimmunoassay (RIA), immunoradiometric assays (IRMA) and immunoenzymatic assays (IEMA), including sandwich assays using monoclonal and/or polyclonal antibodies.
- Exemplary sandwich assays are described by David et a/., in US Patent Nos. 4,376,110 and 4,486,530, hereby incorporated by reference.
- Antibody staining of cells on slides may be used in methods well known in cytology laboratory diagnostic tests, as well known to those skilled in the art.
- ELISA involves the use of enzymes which give a coloured reaction product, usually in solid phase assays.
- Enzymes such as horseradish peroxidase and phosphatase have been widely employed.
- a way of amplifying the phosphatase reaction is to use NADP as a substrate to generate NAD which now acts as a coenzyme for a second enzyme system.
- Pyrophosphatase from Escherichia coli provides a good conjugate because the enzyme is not present in tissues, is stable and gives a good reaction colour.
- Chemi-luminescent systems based on enzymes such as luciferase can also be used.
- Vitamin biotin Conjugation with the vitamin biotin is frequently used since this can readily be detected by its reaction with enzyme-linked avidin or streptavidin to which it binds with great specificity and affinity.
- nucleic acid e.g. mRNA
- methods for detection and/or measurement of nucleic acid include southern blot, northern blot, polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), quantitative real-time PCR (qRT-PCR), nanoarray, microarray, macroarray, autoradiography and in situ hybridisation.
- the method further comprises the steps of: c) exposing a separate population of the dendritic cells or dendritic-like cells to one or more negative control agent that is not a respiratory sensitizer in mammals; and
- step (d) measuring in the cells the expression of the one or more biomarker(s) measured in step (b) wherein the test agent is identified as a respiratory sensitizer in the event that the presence and/or amount in the test sample of the one or more biomarker measured in step (b) is different from the presence and/or amount in the control sample of the one or more biomarkers measured in step (d).
- the expression of the one or more biomarker in the cell population exposed to the test agent is: less than or equal to 80% of that of the cell population exposed to the negative control agent, for example, no more than 79%, 78%, 77%, 76%, 75%, 74%, 73%, 72%, 71%, 70%, 69%, 68%, 67%, 66%, 65%, 64%, 63%, 62%, 61 %, 60%, 59%, 58%, 57%, 56%, 55%, 54%, 53%, 52%, 51%, 50%,
- the one or more negative control agent may comprise or consist of one or more agent selected from the group consisting of 1-butanol, 4-aminobenzoic acid, chlorobenzene, dimethyl formamide, ethyl vanillin, isopropanol, methyl salicylate, propylene glycol, potassium permanganate, Tween 80TM (polyoxyethylene (20) sorbitan monooleate) and zinc sulphate (i.e., the group of non-sensitizers defined in Table 2).
- agent selected from the group consisting of 1-butanol, 4-aminobenzoic acid, chlorobenzene, dimethyl formamide, ethyl vanillin, isopropanol, methyl salicylate, propylene glycol, potassium permanganate, Tween 80TM (polyoxyethylene (20) sorbitan monooleate) and zinc sulphate (i.e., the group of non-sensitizers defined in Table 2).
- the negative control agent may be a solvent for use with the test or control agents of the invention.
- the negative control may be DMSO and/or distilled water.
- the expression of the one or more biomarkers measured in step (b) of the dendritic cells or dendritic-like cells prior to test agent exposure is used as a negative control.
- a further embodiment comprises the steps of: e) exposing a separate population of the dendritic cells or dendritic-like cells to one or more positive control agent that is a respiratory sensitizer in a mammal; and
- step (b) measuring in the cells the expression of the one or more biomarker(s) measured in step (b) wherein the test agent is identified as a respiratory sensitizer in the event that the presence and/or amount in the test sample of the one or more biomarker measured in step (f) corresponds to the presence and/or amount in the one or more positive control sample of the one or more biomarker measured in step (b).
- the expression of the one or more biomarker in the cell population exposed to the test agent is identical to, or does not differ significantly from, that of the cell population exposed to the one more positive control agent.
- the expression of the one or more biomarker in the cell population exposed to the test agent is between 81% and 119% of that of the cell population exposed to the one more positive control agent, for example, greater than or equal to 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of that of the cell population exposed to the one more positive control agent, and less than or equal to 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118% or 119% of that of the cell population exposed to the
- the method may include measuring PIP3-E expression.
- the method may include measuring BTNL8 expression.
- the method may include measuring CLEC4A expression.
- the method may include measuring HIST4H4 expression.
- the method may include measuring YKT6 expression.
- the method may include measuring FLJ32679 /// GOLGA8G /// GOLGA8E expression.
- the method may include measuring PACSIN3 expression.
- the method may include measuring PDE1B expression.
- the method may include measuring NQ01 expression.
- the method may include measuring CAMK1 D expression.
- the method may include measuring MYB expression.
- the method may include measuring ENST00000387396 expression.
- the method may include measuring GRK5 expression.
- the method may include measuring CD86 expression.
- the method may include measuring CD1A expression.
- the method may include measuring WWOX expression.
- the method may include measuring IKZF2 expression.
- the method may include measuring FUCA1 expression.
- the method may include measuring C10orf76 expression.
- the method may include measuring AMICA1 expression.
- the method may include measuring PDPK2 /// PDPK1 expression.
- the method may include measuring AZU1 expression.
- the method may include measuring ACN9 expression.
- the method may include measuring PDPN expression.
- the method may include measuring LOC642587 expression.
- the method may include measuring SEC61A2 expression.
- the method may include measuring ELA2 expression.
- the method may include measuring BMP2K expression.
- the method may include measuring HCCS expression.
- the method may include measuring CXorf26 expression.
- the method may include measuring TYSND1 expression.
- the method may include measuring CARS expression.
- the method may include measuring NECAP1 expression.
- the method may include measuring CDH26 expression.
- the method may include measuring SERPINB1 expression.
- the method may include measuring STEAP4 expression.
- the method may include measuring TXNIP expression.
- the method may include measuring ENST00000386628 expression.
- the method may include measuring C12orf35 expression.
- the method may include measuring HMGA2 expression.
- the method may include measuring KRT16 expression.
- the method may include measuring GGTLC2 expression.
- the method may include measuring ENST00000386437 expression.
- the method may include measuring OSBPL11 expression.
- the method may include measuring FAM71 F1 expression.
- the method may include measuring ATP6V1 B2 expression.
- the method may include measuring LOC128102 expression.
- the method may include measuring TBX19 expression.
- the method may include measuring NID1 expression.
- the method may include measuring LPXN expression.
- the method may include measuring C15orf45 expression.
- the method may include measuring RNF111 expression.
- the method may include measuring ENST00000386861 expression.
- the method may include measuring CD33 expression.
- the method may include measuring TANK expression.
- the method may include measuring ANKRD44 expression.
- the method may include measuring WDFY1 expression.
- the method may include measuring SDC4 expression.
- the method may include measuring TMPRSS11 B expression.
- the method may include measuring AFF4 expression.
- the method may include measuring HBEGF expression.
- the method may include measuring XK expression.
- the method may include measuring SLAMF7 expression.
- the method may include measuring S100A4 expression.
- the method may include measuring MPZL3 expression.
- the method may include measuring GENSCAN00000044853 expression.
- the method may include measuring TRAV8-3 expression.
- the method may include measuring LOC100131497 expression.
- the method may include measuring KIAA1468 expression.
- the method may include measuring SPHK2 expression.
- the method may include measuring ENST00000309260 expression.
- the method may include measuring CCR6 expression.
- the method may include measuring GSTA3 expression.
- the method may include measuring RALA expression.
- the method may include measuring C7orf53 expression.
- the method may include measuring AF480566 expression.
- the method may include measuring CERCAM expression.
- the method may include measuring hsa-mir-147 expression.
- the method may include measuring NFYC expression.
- the method may include measuring CD53 expression.
- the method may include measuring PSEN2 expression.
- the method may include measuring CISD1 expression.
- the method may include measuring SCD expression.
- the method may include measuring MED19 expression.
- the method may include measuring SYT17 expression.
- the method may include measuring KRT16 /// LOC400578 /// MGC102966 expression.
- the method may include measuring C18orf51 expression.
- the method may include measuring CD79A expression.
- the method may include measuring C19orf56 expression.
- the method may include measuring AGFG1 expression.
- the method may include measuring FOXP1 expression.
- the method may include measuring TLR6 expression.
- the method may include measuring SUSD3 expression.
- the method may include measuring ENST00000387842 expression.
- the method may include measuring ENST00000387842 expression.
- the method may include measuring GPA33 expression.
- the method may include measuring CDC123 expression.
- the method may include measuring C10orf11 expression.
- the method may include measuring ENST00000322493 expression.
- the method may include measuring PTMAP7 expression.
- the method may include measuring ARRDC4 expression.
- the method may include measuring ENST00000388199 expression.
- the method may include measuring ENST00000388437 expression.
- the method may include measuring KRT9 expression.
- the method may include measuring ENST00000379371 expression.
- the method may include measuring HDAC4 expression.
- the method may include measuring CD200 expression.
- the method may include measuring PAPSS1 expression.
- the method may include measuring ORAI2 expression.
- the method may include measuring AK124536 expression.
- the method may include measuring ZBTB10 expression.
- the method may include measuring ENST00000387422 expression.
- the method may include measuring RAB9A expression.
- the method may include measuring 78956 3 expression.
- the method may include measuring DRD5 expression.
- the method may include measuring CNR2 expression.
- the method may include measuring OIT3 expression.
- the method may include measuring ENST00000386981 expression.
- the method may include measuring C10orf90 expression.
- the method may include measuring OR52D1 expression.
- the method may include measuring ZNF214 expression.
- the method may include measuring ENST00000386959 expression.
- the method may include measuring ART4 expression.
- the method may include measuring RCBTB2 expression.
- the method may include measuring HOMER2 expression.
- the method may include measuring WWP2 expression.
- the method may include measuring WDR24 expression.
- the method may include measuring MED31 expression.
- the method may include measuring CALM2 expression.
- the method may include measuring DLX2 expression.
- the method may include measuring BTBD3 expression.
- the method may include measuring ENST00000339367 expression.
- the method may include measuring TBCA expression.
- the method may include measuring GIN1 expression.
- the method may include measuring NOL7 expression.
- the method may include measuring ENST00000402365 expression.
- the method may include measuring C7orf28B /// C7orf28A expression.
- the method may include measuring DPP7 expression.
- the method may include measuring hCG_1749005 expression.
- the method may include measuring PNPLA4 expression.
- the method may include measuring USP51 expression.
- the method may include measuring HLA-DQA1 /// HLA-DRA expression.
- the method may include measuring FAAH expression.
- the method may include measuring GDAP2 expression.
- the method may include measuring CD48 expression.
- the method may include measuring PTPRJ expression.
- the method may include measuring EXPH5 expression.
- the method may include measuring RPS26 /// LOC728937 /// RPS26L /// hCG_2033311 expression.
- the method may include measuring ALDH2 expression.
- the method may include measuring CALM1 expression.
- the method may include measuring NOX5 /// SPESP1 expression.
- the method may include measuring RHBDL1 expression.
- the method may include measuring CYLD expression.
- the method may include measuring OSBPL1A expression.
- the method may include measuring GYPC expression.
- the method may include measuring RQCD1 expression.
- the method may include measuring RBM44 expression.
- the method may include measuring ENST00000384680 expression.
- the method may include measuring C3orf58 expression.
- the method may include measuring MFSD1 expression.
- the method may include measuring HACL1 expression.
- the method may include measuring SATB1 expression.
- the method may include measuring USP4 expression.
- the method may include measuring ENST00000410125 expression.
- the method may include measuring ENST00000384055 expression.
- IThe method may include measuring L7R expression.
- the method may include measuring ENST00000364497 expression.
- the method may include measuring FAM135A expression.
- the method may include measuring CD164 expression.
- the method may include measuring DYNLT1 expression.
- the method may include measuring NRCAM expression.
- the method may include measuring ZNF596 expression.
- the method may include measuring ENST00000332418 expression.
- the method may include measuring TCEAL3 /// TCEAL6 expression.
- the method may include measuring SNAPIN expression.
- the method may include measuring DENND2D expression.
- the method may include measuring SAMD8 expression.
- the method may include measuring LHPP expression.
- the method may include measuring SLC37A2 expression.
- the method may include measuring FLU /// EWSR1 expression.
- the method may include measuring OR9G4 expression.
- the method may include measuring LOC338799 expression.
- the method may include measuring HEXDC expression.
- the method may include measuring NOTUM expression.
- the method may include measuring MCOLN1 expression.
- the method may include measuring PRKACA expression.
- the method may include measuring CRIM1 expression.
- the method may include measuring CECR5 expression.
- the method may include measuring RNF13 expression.
- the method may include measuring 40969 expression.
- the method may include measuring ZNF366 expression.
- the method may include measuring ENST00000410754 expression.
- the method may include measuring GIMAP5 expression.
- the method may include measuring ENST00000362484 expression.
- the method may include measuring TFE3 expression.
- the method may include measuring RHOU expression.
- the method may include measuring MED8 expression.
- the method may include measuring CASQ2 expression.
- the method may include measuring NUDT5 expression.
- the method may include measuring C11orf73 expression.
- the method may include measuring PAK1 expression.
- the method may include measuring PRSS21 expression.
- the method may include measuring ENST00000332418 expression.
- the method may include measuring BTBD12 expression.
- the method may include measuring DHRS13 expression.
- the method may include measuring CCDC102B expression.
- the method may include measuring BCL2 expression.
- the method may include measuring ZNF211 /// ZNF134 expression.
- the method may include measuring NDUFV2 expression.
- the method may include measuring MYCN expression.
- the method may include measuring ENST00000385528 expression.
- the method may include measuring ENST00000264275 expression.
- the method may include measuring CASP8 expression.
- the method may include measuring RTN4 expression.
- the method may include measuring PLCG1 expression.
- the method may include measuring MGC42105 expression.
- the method may include measuring EMB expression.
- the method may include measuring ENST00000386433 expression.
- the method may include measuring COL21A1 expression.
- the method may include measuring LRP12 expression.
- the method may include measuring LMNA expression.
- the method may include measuring ENST00000385567 expression.
- the method may include measuring ENST00000362863 expression.
- the method may include measuring ZNF503 expression.
- the method may include measuring NLRX1 expression.
- the method may include measuring ENST00000391173 expression.
- the method may include measuring NDRG2 expression.
- the method may include measuring TRAF7 expression.
- the method may include measuring KRT40 expression.
- the method may include measuring KRT40 expression.
- the method may include measuring DRD5 expression.
- the method may include measuring ZC3H8 expression.
- the method may include measuring MMP9 expression.
- the method may include measuring PLTP expression.
- the method may include measuring ENST00000362686 expression.
- the method may include measuring SPEF2 expression.
- the method may include measuring LRRC16A expression.
- the method may include measuring FBX09 expression.
- the method may include measuring EEPD1 expression.
- the method may include measuring FCN1 expression.
- the method may include measuring EFNA3 expression.
- the method may include measuring ENST00000314893 expression.
- the method may include measuring TMEM19 expression.
- the method may include measuring PLXNC1 expression.
- the method may include measuring NHLRC3 expression.
- the method may include measuring MBNL2 expression.
- the method may include measuring EIF5 expression.
- the method may include measuring PLEKHG4 expression.
- the method may include measuring COPS3 expression.
- the method may include measuring FAM171A2 expression.
- the method may include measuring LOC653653 /// AP1S2 expression.
- the method may include measuring VAPA expression.
- the method may include measuring MATK expression.
- the method may include measuring ACTR2 expression.
- the method may include measuring BPI expression.
- the method may include measuring ERG expression.
- the method may include measuring LAMB2 expression.
- the method may include measuring BC090058 expression.
- the method may include measuring PHTF2 expression.
- the method may include measuring ENST00000333261 expression.
- the method may include measuring C8orf55 expression.
- the method may include measuring PDE7A expression.
- the method may include measuring NAPRT1 expression.
- the method may include measuring HLA-DRA expression.
- the method may include measuring SLC22A15 expression.
- the method may include measuring FCGR1A /// FCGR1 B /// FCGR1C expression.
- the method may include measuring SLC27A3 expression.
- the method may include measuring ID3 expression.
- the method may include measuring TBCEL expression.
- the method may include measuring FAM138D expression.
- the method may include measuring POMP expression.
- the method may include measuring SNN expression.
- the method may include measuring MED13 expression.
- the method may include measuring ZFP36L2 expression.
- the method may include measuring UXS1 expression.
- the method may include measuring CD40 expression.
- the method may include measuring ENST00000362620 expression.
- the method may include measuring GGT5 expression.
- the method may include measuring BC035666 expression.
- the method may include measuring G6PD expression.
- the method may include measuring ENST00000384272 expression.
- the method may include measuring CLCC1 expression.
- the method may include measuring SCGB2A1 expression.
- the method may include measuring GAA expression.
- the method may include measuring SERPINB2 expression.
- the method may include measuring GPI expression.
- the method may include measuring LASS6 expression.
- the method may include measuring EIF4A2 expression.
- the method may include measuring HLA-DRA expression.
- the method may include measuring ENST00000385586 expression.
- the method may include measuring ANXA2P2 expression.
- the method may include measuring FANCG expression.
- the method may include measuring FAM53B expression.
- the method may include measuring RFXAP expression.
- the method may include measuring UBR1 expression.
- the method may include measuring TBC1 D2B expression.
- the method may include measuring SERPINB10 expression.
- the method may include measuring SEC23B expression.
- the method may include measuring MN1 expression.
- the method may include measuring CRTAP expression.
- the method may comprise or consist of measuring, in step (b), the expression of one or more biomarkers defined in Table 1A, for example, at least 2 of the biomarkers defined in Table 1A.
- the method may comprise measuring the expression of OR5B21.
- the method may comprise measuring the expression of SLC7A7.
- the method comprises or consists of measuring the expression of OR5B21 and SLC7A7 in step (b).
- the method may additionally or alternatively comprise or consist of, measuring in step (b) the expression of one or more biomarkers defined in Table 1 B, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13 of the biomarkers defined in Table 1 B.
- the method may additionally or alternatively comprise or consist of, measuring in step (b) the expression of one or more biomarkers defined in Table 1C, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, 100, 101 , 102,
- the expression of all of the biomarkers defined in Table 1A and/or all of the biomarkers defined in Table 1 B and/or all of the biomarkers defined in Table 1C may be measured in step (b).
- the method may comprise or consist of measuring in step (b) all of the biomarkers defined in Table 1.
- step (b) comprises or consists of measuring the expression of a nucleic acid molecule encoding the one or more biomarker(s).
- the nucleic acid molecule may be a cDNA molecule or an mRNA molecule.
- the nucleic acid molecule is an mRNA molecule.
- the nucleic acid molecule may be a cDNA molecule.
- the expression of the one or more biomarker(s) in step (b) is performed using a method selected from the group consisting of Southern hybridisation, Northern hybridisation, polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), quantitative real-time PCR (qRT-PCR), nanoarray, microarray, macroarray, autoradiography and in situ hybridisation.
- the expression of the one or more biomarker(s) is measured using a DNA microarray.
- the method may comprise measuring the expression of the one or more biomarker(s) in step (b) using one or more binding moieties, each capable of binding selectively to a nucleic acid molecule encoding one of the biomarkers identified in Table 1.
- the one or more binding moieties each comprise or consist of a nucleic acid molecule. In a further embodiment the one or more binding moieties each comprise or consist of DNA, RNA, PNA, LNA, GNA, TNA or PMO. Preferably, the one or more binding moieties each comprise or consist of DNA. In one embodiment, the one or more binding moieties are 5 to 100 nucleotides in length. However, in an alternative embodiment, they are 15 to 35 nucleotides in length.
- Suitable binding agents may be selected or screened from a library based on their ability to bind a given nucleic acid, protein or amino acid motif, as discussed below.
- the binding moiety comprises a detectable moiety.
- detecttable moiety we include a moiety which permits its presence and/or relative amount and/or location (for example, the location on an array) to be determined, either directly or indirectly.
- the detectable moiety may be a fluorescent and/or luminescent and/or chemiluminescent moiety which, when exposed to specific conditions, may be detected.
- a fluorescent moiety may need to be exposed to radiation (i.e. light) at a specific wavelength and intensity to cause excitation of the fluorescent moiety, thereby enabling it to emit detectable fluorescence at a specific wavelength that may be detected.
- the detectable moiety may be an enzyme which is capable of converting a (preferably undetectable) substrate into a detectable product that can be visualised and/or detected. Examples of suitable enzymes are discussed in more detail below in relation to, for example, ELISA assays.
- the detectable moiety may be selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety (for example, a radioactive atom); or an enzymatic moiety.
- the detectable moiety comprises or consists of a radioactive atom.
- the radioactive atom may be selected from the group consisting of technetium-99m, iodine-123, iodine-125, iodine-131 , indium-111 , fluorine-19, carbon-13, nitrogen-15, oxygen-17, phosphorus-32, sulphur-35, deuterium, tritium, rhenium-186, rhenium-188 and yttrium-90.
- the agent to be detected (such as, for example, the one or more biomarkers in the test sample and/or control sample described herein and/or an antibody molecule for use in detecting a selected protein) must have sufficient of the appropriate atomic isotopes in order for the detectable moiety to be readily detectable.
- the detectable moiety of the binding moiety is a fluorescent moiety.
- the radio- or other labels may be incorporated into the biomarkers present in the samples of the methods of the invention and/or the binding moieties of the invention in known ways.
- the binding agent is a polypeptide it may be biosynthesised or may be synthesised by chemical amino acid synthesis using suitable amino acid precursors involving, for example, fluorine-19 in place of hydrogen.
- Labels such as 99m Tc, 23 l, 86 Rh, 188 Rh and 1 ln can, for example, be attached via cysteine residues in the binding moiety.
- Yttrium-90 can be attached via a lysine residue.
- the IODOGEN method (Fraker ef a/ (1978) Biochem. Biophys. Res. Comm.
- biomarkers in the sample(s) to be tested may be labelled with a moiety which indirectly assists with determining the presence, amount and/or location of said proteins.
- the moiety may constitute one component of a multicomponent detectable moiety.
- the biomarkers in the sample(s) to be tested may be labelled with biotin, which allows their subsequent detection using streptavidin fused or otherwise joined to a detectable label.
- the method provided in the first aspect of the present invention may comprise or consist of, in step (b), determining the expression of the protein of the one or more biomarker defined in Table 1.
- the method may comprise measuring the expression of the one or more biomarker(s) in step (b) using one or more binding moieties each capable of binding selectively to one of the biomarkers identified in Table 1.
- the one or more binding moieties may comprise or consist of an antibody or an antigen- binding fragment thereof such as a monoclonal antibody or fragment thereof.
- antibody includes any synthetic antibodies, recombinant antibodies or antibody hybrids, such as but not limited to, a single-chain antibody molecule produced by phage-display of immunoglobulin light and/or heavy chain variable and/or constant regions, or other immunointeractive molecules capable of binding to an antigen in an immunoassay format that is known to those skilled in the art.
- antibody-like binding agents such as affibodies and aptamers.
- one or more of the first binding molecules may be an aptamer (see Collett et al., 2005, Methods 37:4-15).
- Molecular libraries such as antibody libraries (Clackson et al, 1991 , Nature 352, 624- 628; Marks ef al, 1991 , J Mol Biol 222(3): 581-97), peptide libraries (Smith, 1985, Science 228(4705): 1315-7), expressed cDNA libraries (Santi et al (2000) J Mol Biol 296(2): 497-508), libraries on other scaffolds than the antibody framework such as affibodies (Gunneriusson ef al, 1999, Appl Environ Microbiol 65(9): 4134-40) or libraries based on aptamers (Kenan et al, 1999, Methods Mol Biol 118, 217-31) may be used as a source from which binding molecules that are specific for a given motif are selected for use in the methods of the invention.
- the molecular libraries may be expressed in vivo in prokaryotic cells (Clackson et al, 1991 , op. cit; Marks et al, 1991 , op. cit.) or eukaryotic cells (Kieke ef al, 1999, Proc Natl Acad Sci USA, 96(10):5651-6) or may be expressed in vitro without involvement of cells (Hanes & Pluckthun, 1997, Proc Natl Acad Sci USA 94(10):4937-42; He & Taussig, 1997, Nucleic Acids Res 25(24):5132-4; Nemoto ef al, 1997, FEBS Lett, 414(2):405-8).
- filamentous bacteriophage displaying antibody fragments at their surfaces, the antibody fragments being expressed as a fusion to the minor coat protein of the bacteriophage (Clackson ef al, 1991 , supra; Marks ef al, 1991 , supra).
- suitable systems for display include using other viruses (EP 39578), bacteria (Gunneriusson ef al, 1999, supra; Daughterly ef al, 1998, Protein Eng 11(9):825-32; Daugherty et al, 1999, Protein Eng 12(7):613-21), and yeast (Shusta et al, 1999, Mo/ ⁇ / ⁇ / 292(5):949-56).
- variable heavy (V H ) and variable light (V L ) domains of the antibody are involved in antigen recognition, a fact first recognised by early protease digestion experiments. Further confirmation was found by "humanisation" of rodent antibodies. Variable domains of rodent origin may be fused to constant domains of human origin such that the resultant antibody retains the antigenic specificity of the rodent parented antibody (Morrison ef al (1984) Proc. Natl. Acad. Sci. USA 81, 6851-6855).
- variable domains that antigenic specificity is conferred by variable domains and is independent of the constant domains is known from experiments involving the bacterial expression of antibody fragments, all containing one or more variable domains.
- variable domains include Fab-like molecules (Better ef al (1988) Science 240, 1041); Fv molecules (Skerra et al (1988) Science 240, 1038); single-chain Fv (ScFv) molecules where the V H and V L partner domains are linked via a flexible oligopeptide (Bird et al (1988) Science 242, 423; Huston et al (1988) Proc. Natl. Acad. Sci.
- the antibody or antigen-binding fragment may be selected from the group consisting of intact antibodies, Fv fragments (e.g. single chain Fv and disulphide-bonded Fv), Fab-like fragments (e.g. Fab fragments, Fab' fragments and F(ab) 2 fragments), single variable domains (e.g. V H and V L domains) and domain antibodies (dAbs, including single and dual formats [i.e. dAb-linker-dAb]).
- Fv fragments e.g. single chain Fv and disulphide-bonded Fv
- Fab-like fragments e.g. Fab fragments, Fab' fragments and F(ab) 2 fragments
- single variable domains e.g. V H and V L domains
- dAbs including single and dual formats [i.e. dAb-linker-dAb]
- the antibody or antigen- binding fragment is a single chain Fv (scFv).
- the one or more binding moieties may alternatively comprise or consist of an antibody-like binding agent, for example an affibody or aptamer.
- scFv molecules we mean molecules wherein the V H and V L partner domains are linked via a flexible oligopeptide.
- the antibodies may be monoclonal or polyclonal. Suitable monoclonal antibodies may be prepared by known techniques, for example those disclosed in “Monoclonal Antibodies: A manual of techniques", H Zola (CRC Press, 1988) and in “Monoclonal Hybridoma Antibodies: Techniques and applications", J G R Hurrell (CRC Press, 1982), both of which are incorporated herein by reference.
- selector peptides having defined motifs are usually employed.
- Amino acid residues that provide structure, decreasing flexibility in the peptide or charged, polar or hydrophobic side chains allowing interaction with the binding molecule may be used in the design of motifs for selector peptides. For example:
- Proline may stabilise a peptide structure as its side chain is bound both to the alpha carbon as well as the nitrogen;
- Phenylalanine, tyrosine and tryptophan have aromatic side chains and are highly hydrophobic, whereas leucine and isoleucine have aliphatic side chains and are also hydrophobic;
- Lysine, arginine and histidine have basic side chains and will be positively charged at neutral pH, whereas aspartate and glutamate have acidic side chains and will be negatively charged at neutral pH;
- Asparagine and glutamine are neutral at neutral pH but contain a amide group which may participate in hydrogen bonds;
- Serine, threonine and tyrosine side chains contain hydroxyl groups, which may participate in hydrogen bonds.
- binding molecules may involve the use of array technologies and systems to analyse binding to spots corresponding to types of binding molecules.
- the one or more protein-binding moieties may comprise a detectable moiety.
- the detectable moiety may be selected from the group consisting of a fluorescent moiety, a luminescent moiety, a chemiluminescent moiety, a radioactive moiety and an enzymatic moiety.
- step (b) may be performed using an assay comprising a second binding agent capable of binding to the one or more proteins, the second binding agent also comprising a detectable moiety.
- a second binding agent capable of binding to the one or more proteins
- the second binding agent also comprising a detectable moiety.
- Suitable second binding agents are described in detail above in relation to the first binding agents.
- the proteins of interest in the sample to be tested may first be isolated and/or immobilised using the first binding agent, after which the presence and/or relative amount of said biomarkers may be determined using a second binding agent.
- the second binding agent is an antibody or antigen-binding fragment thereof; typically a recombinant antibody or fragment thereof.
- the antibody or fragment thereof is selected from the group consisting of: scFv; Fab; a binding domain of an immunoglobulin molecule. Suitable antibodies and fragments, and methods for making the same, are described in detail above.
- the second binding agent may be an antibody-like binding agent, such as an affibody or aptamer.
- the detectable moiety on the protein in the sample to be tested comprises or consists of a member of a specific binding pair (e.g. biotin)
- the second binding agent may comprise or consist of the complimentary member of the specific binding pair (e.g. streptavidin).
- the detectable moiety is selected from the group consisting of: a fluorescent moiety; a luminescent moiety; a chemiluminescent moiety; a radioactive moiety; an enzymatic moiety.
- suitable detectable moieties for use in the methods of the invention are described above.
- Preferred assays for detecting serum or plasma proteins include enzyme linked immunosorbent assays (ELISA), radioimmunoassay (RIA), immunoradiometric assays (IRMA) and immunoenzymatic assays (IEMA), including sandwich assays using monoclonal and/or polyclonal antibodies. Exemplary sandwich assays are described by David et al in US Patent Nos. 4,376,110 and 4,486,530, hereby incorporated by reference. Antibody staining of cells on slides may be used in methods well known in cytology laboratory diagnostic tests, as well known to those skilled in the art.
- the assay is an ELISA (Enzyme Linked Immunosorbent Assay) which typically involves the use of enzymes which give a coloured reaction product, usually in solid phase assays.
- Enzymes such as horseradish peroxidase and phosphatase have been widely employed.
- a way of amplifying the phosphatase reaction is to use NADP as a substrate to generate NAD which now acts as a coenzyme for a second enzyme system.
- Pyrophosphatase from Escherichia coli provides a good conjugate because the enzyme is not present in tissues, is stable and gives a good reaction colour.
- Chemiluminescent systems based on enzymes such as luciferase can also be used.
- Vitamin biotin Conjugation with the vitamin biotin is frequently used since this can readily be detected by its reaction with enzyme-linked avidin or streptavidin to which it binds with great specificity and affinity.
- the assay used for protein detection is conveniently a fluorometric assay.
- the detectable moiety of the second binding agent may be a fluorescent moiety, such as an Alexa fluorophore (for example Alexa-647).
- step (b) is performed using an array.
- the array may be a bead-based array or a surface-based array.
- the array may be selected from the group consisting of: macroarray; microarray; nanoarray.
- the method is for identifying agents capable of inducing a respiratory hypersensitivity response.
- the hypersensitivity response is a humoral hypersensitivity response, for example, a type I hypersensitivity response.
- the method is for identifying agents capable of inducing respiratory allergy.
- the population of dendritic cells or population of dendritic-like cells is a population of dendritic cells.
- the dendritic cells are primary dendritic cells.
- the dendritic cells are myeloid dendritic cells.
- the population of dendritic cells or dendritic-like cells is preferably mammalian in origin.
- the mammal is a rat, mouse, guinea pig, cat, dog, horse or a primate. Most preferably, the mammal is human.
- the population of dendritic cells or population of dendritic-like cells is a population of dendritic-like cells, preferably myeloid dendritic-like cells.
- the dendritic-like cells express at least one of the markers selected from the group consisting of CD54, CD86, CD80, HLA-DR, CD14, CD34 and CD1a, for example, 2, 3, 4, 5, 6 or 7 of the markers.
- the dendritic-like cells express the markers CD54, CD86, CD80, HLA-DR, CD14, CD34 and CD1a.
- the dendritic-like cells may be derived from myeloid dendritic cells.
- the dendritic-like cells are myeloid leukaemia-derived cells.
- the myeloid leukaemia-derived cells are selected from the group consisting of KG-1 , THP-1 , U-937, HL-60, Monomac-6, AML-193 and MUTZ-3.
- dendritic-like cells are MUTZ-3 cells.
- MUTZ-3 cells are human acute myelomonocytic leukemia cells that were available from 15 May 1995 under deposit number ACC 295 from Deutsche Sammlung fur Mikroorganismen und Zellkulturen GmbH (DSMZ), InhoffenstraBe 7B, Braunschweig, Germany (www.dsmz.de).
- the dendritic-like cells after stimulation with cytokine, present antigens through CD1d, MHC class I and II and/or induce specific T-cell proliferation.
- the one or more negative control agent comprises or consists of one or more agent selected from the group consisting of 1-butanol, 4-aminobenzoic acid, chlorobenzene, dimethyl formamide, ethyl vanillin, isopropanol, methyl salicylate, propylene glycol, potassium permanganate, Tween 80TM (polyoxyethylene (20) sorbitan monooleate) and zinc sulphate (i.e., the group of non-sensitizers defined in Table 2).
- step (c) may comprise or consist of exposing separate populations of the dendritic cells or dendritic-like cells to each of the negative control agents defined in Table 2.
- the method may comprise or consist of the use of at least 2 negative control agents (i.e. non-sensitizing agents), for example, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99 or at least 00 negative control agents.
- the one or more positive control agent comprises or consists of one or more agent selected from the group consisting of ammonium hexachloroplatinate, ammonium persulfate, glutaraldehyde, hexamethylen diisocyanate, maleic anhydride, methylene diphenol diisocyanate, phtalic anhydride, toluendiisocyanate and trimellitic anhydride (i.e., the group of sensitizers defined in Table 2).
- step (d) may comprise or consist of exposing separate populations of the dendritic cells or dendritic-like cells to each of the positive control agents defined in Table 2.
- the method may comprise or consist of the use of at least 2 positive control (i.e. sensitizing agents), for example, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or at least 100 positive control agents.
- at least 2 positive control i
- the method is indicative of whether the test agent is or is not a respiratory sensitizing agent.
- the method is indicative of the respiratory sensitizing potency of the sample to be tested.
- the method is indicative of the sensitizer potency of the test agent (i.e., that the test agent is either, a non-sensitizer, a weak sensitizer, a moderate sensitizer, a strong sensitizer or an extreme sensitizer).
- the decision value and distance in PCA correlates with sensitizer potency.
- test agent potency may be determined by, in step (e), providing:
- test agent is identified as an extreme respiratory sensitizer in the event that the presence and/or amount in the test sample of the one or more biomarker measured in step (b) corresponds to the presence and/or amount in the extreme positive control sample (where present) of the one or more biomarker measured in step (f); and/or is different from the presence and/or amount in the strong, moderate, weak and/or negative control sample (where present) of the one or more biomarkers measured in step (f), wherein the test agent is identified as a strong respiratory sensitizer in the event that the presence and/or amount in the test sample of the one or more biomarker measured in step (b) corresponds to the presence and/or amount in the strong positive control sample (where present) of the one or more biomarker measured in step (f); and/or is different from the presence and/or amount in the extreme, moderate, weak and/or negative control sample (where present) of the one or more biomarkers measured in step (f), wherein
- step (e) may comprise or consist of providing the following categories of respiratory sensitizer positive control:
- Negative and positive controls may be classified as respiratory non-sensitizers or respiratory sensitizers, respectively, based on clinical observations in humans.
- the method may comprise comparing the expression of the one or more biomaker measured in step (b) with one or more predetermined reference value representing the expression of the one or more biomarker measured in step (c) and/or step (e).
- respiratory sensitizing agents are determined with an ROC AUC of at least 0.55, for example with an ROC AUC of at least, 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, 0.90, 0.95, 0.96, 0.97, 0.98, 0.99 or with an ROC AUC of 1.00.
- skin sensitizing agents are determined with an ROC AUC of at least 0.85, and most preferably with an ROC AUC of 1.
- agents capable of inducing respiratory sensitization are identified using a support vector machine (SVM), such as those available from http://cran.r- project.org/web/packages/e1071/index.html (e.g. e1071 1.5-24).
- SVMs may also be used to determine the ROC AUCs of biomarker signatures comprising or consisting of one or more Table 1 biomarkers as defined herein.
- Support vector machines are a set of related supervised learning methods used for classification and regression. Given a set of training examples, each marked as belonging to one of two categories, an SVM training algorithm builds a model that predicts whether a new example falls into one category or the other.
- an SVM model is a representation of the examples as points in space, mapped so that the examples of the separate categories are divided by a clear gap that is as wide as possible. New examples are then mapped into that same space and predicted to belong to a category based on which side of the gap they fall on. More formally, a support vector machine constructs a hyperplane or set of hyperplanes in a high or infinite dimensional space, which can be used for classification, regression or other tasks.
- the SVM is 'trained' prior to performing the methods of the invention using biomarker profiles of known agents (namely, known sensitizing or non-sensitizing agents). By running such training samples, the SVM is able to learn what biomarker profiles are associated with agents capable of inducing sensitization. Once the training process is complete, the SVM is then able whether or not the biomarker sample tested is from a sensitizing agent or a non-sensitizing agent.
- test agents can be classified as sensitizing or non-sensitizing.
- sensitizing agents of known potency i.e. non-sensitizing, weak, moderate, strong or extreme sensitizing agents
- this training procedure can be by-passed by pre-programming the SVM with the necessary training parameters.
- agents capable of inducing sensitization can be identified according to the known SVM parameters using the SVM algorithm detailed in Table 3, based on the measurement of all the biomarkers listed in Table 1.
- suitable SVM parameters can be determined for any combination of the biomarkers listed Table 1 by training an SVM machine with the appropriate selection of data (i.e. biomarker measurements from cells exposed to known sensitizing and/or non-sensitizing agents).
- the Table 1 biomarkers may be used to identify agents capable of inducing respiratory sensitization according to any other suitable statistical method known in the art.
- the Table 1 data may be used to identify agents capable of inducing respiratory sensitization according to any other suitable statistical method known in the art (e.g., ANOVA, ANCOVA, MANOVA, MANCOVA, Multivariate regression analysis, Principal components analysis (PCA), .Factor analysis, Canonical correlation analysis, Canonical correlation analysis, Redundancy analysis Correspondence analysis (CA; reciprocal averaging), Multidimensional scaling, Discriminant analysis, Linear discriminant analysis (LDA), .Clustering systems, Recursive partitioning and Artificial neural networks).
- ANOVA Principal components analysis
- CA Redundancy analysis Correspondence analysis
- LDA Linear discriminant analysis
- .Clustering systems Recursive partitioning and Artificial neural networks.
- the method of the invention has an accuracy of at least 65%, for example 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% accuracy.
- the method of the invention has a sensitivity of at least 65%, for example 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sensitivity.
- the method of the invention has a specificity of at least 65%, for example 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% specificity.
- the method of the first aspect of the invention comprises concurrently or consecutively performing a method for identifying agents capable of inducing sensitization of mammalian skin described in PCT publication number WO 2012/056236 which is incorporated herein by reference.
- the method for identifying agents capable of inducing sensitization of mammalian skin is performed concurrently with the method of the first aspect of the present invention (i.e., determining whether a test compound is a skin and/or respiratory sensitizer by measuring relevant marker expression in the same cell sample(s) exposed to the test agent).
- a second aspect of the invention provides an array for use in the method of the first aspect of the invention (or any embodiment or combination of embodiments thereof), the array comprising one or more binding moieties as defined above.
- the binding moieties are (collectively) capable of binding to all of the biomarkers defined in Table 1A.
- the binding moieties are (collectively) capable of binding to all of the biomarkers defined in Table 3B.
- the binding moieties are (collectively) capable of binding to all of the biomarkers defined in Table 3B.
- the binding moieties are (collectively) capable of binding to all of the biomarkers defined in Table 1.
- the binding moieties may be immobilised.
- Arrays per se are well known in the art. Typically they are formed of a linear or two- dimensional structure having spaced apart (i.e. discrete) regions ("spots"), each having a finite area, formed on the surface of a solid support.
- An array can also be a bead structure where each bead can be identified by a molecular code or colour code or identified in a continuous flow. Analysis can also be performed sequentially where the sample is passed over a series of spots each adsorbing the class of molecules from the solution.
- the solid support is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
- the solid supports may be in the form of tubes, beads, discs, silicon chips, microplates, polyvinylidene difluoride (PVDF) membrane, nitrocellulose membrane, nylon membrane, other porous membrane, non-porous membrane (e.g. plastic, polymer, perspex, silicon, amongst others), a plurality of polymeric pins, or a plurality of microtitre wells, or any other surface suitable for immobilising proteins, polynucleotides and other suitable molecules and/or conducting an immunoassay.
- PVDF polyvinylidene difluoride
- nitrocellulose membrane nitrocellulose membrane
- nylon membrane other porous membrane
- non-porous membrane e.g. plastic, polymer, perspex, silicon, amongst others
- a plurality of polymeric pins e.g. plastic, polymer, perspex, silicon, amongst others
- microtitre wells e.g. plastic, polymer, perspex, silicon,
- affinity coupling of the probes via affinity-tags or similar constructs may be employed.
- affinity-tags or similar constructs may be employed.
- contact or non-contact printing, masking or photolithography the location of each spot can be defined.
- the array is a microarray.
- microarray we include the meaning of an array of regions having a density of discrete regions of at least about 00/cm 2 , and preferably at least about 1000/cm 2 .
- the regions in a microarray have typical dimensions, e.g. diameter, in the range of between about 10-250 ⁇ , and are separated from other regions in the array by about the same distance.
- the array may alternatively be a macroarray or a nanoarray.
- binding molecules discussed above
- the skilled person can manufacture an array using methods well known in the art of molecular biology; see Examples below.
- a third aspect of the present invention provides the use of one or more (preferably two or more) biomarkers selected from the group defined in Table 1A Table 1 B and/or Table 1C in combination for identifying hypersensitivity response sensitising agents.
- biomarkers defined in Table 1A and Table 1 B are used collectively for identifying hypersensitivity response sensitising agents.
- the use is consistent with the method described in the first aspect of the invention, and the embodiments described therein.
- a fourth aspect of the invention provides an analytical kit for use in a method according the first aspect of the invention, comprising or consisting of:
- the analytical kit may comprise one or more control agents.
- the analytical kit comprises or consists of the above features, together with one or more negative control agents and/or one or more positive control agents.
- a fifth aspect of the invention provides a method of treating or preventing a respiratory type I hypersensitivity reaction (such as respiratory asthma) in a patient comprising the steps of:
- step (b) determining whether the one or more test agent provided in step (a) is a respiratory sensitizer using a method provided in the first aspect of the present invention; and (c) where one or more test agent is identified as a respiratory sensitizer, reducing or preventing exposure of the patient to the one or more test agent identified as a respiratory sensitizer.
- the one or more test agent that the patient is or has been exposed to is an agent that the the patient is presently exposed to at least once a month, for example, at least once every two weeks, at least once every week, or at least once every day.
- FIG. 1 Backward elimination of potential biomarkers for respiratory sensitization. 1029 genes, selected by p-value sorting, were used as input. After elimination of 727 genes, a local minimum in KLD was observed. Thus, the remaining 302 genes collectively hold the most information relevant for separating respiratory sensitizers from non-sensitizers. This biomarker signature was termed GARD Respiratory Prediction Signature.
- Figure 2 Principal component analysis based on 302 transcripts chosen by p-value filtering and backward elimination. A complete separation between samples stimulated with respiratory sensitizers (blue) and non-sensitizers (green) is observed.
- Figure 3 Estimation of the predictive power of the GARD Respiratory Prediction Signature using cross-validation. 20 Validation Biomarker Signatures were constructed using 70% of randomly chosen data (train set). The Validation Biomarker Signatures were subsequently used to classify the samples in the remaining 30% of the data (test set). A) ROC AUC distribution following SVM predictions of samples in the test set. B) Representative representation of prediction performance illustrated with principal component analysis.
- Figure 6 Figure 3. Estimation of the predictive power of the GRPS using an external test set and cross-validation.
- a panel of 20 chemical compounds, consisting of 9 respiratory sensitizers and 11 non-sensitizers were used for cell stimulations.
- the sensitizers were glutaraldehyde, ammonium persulfate, phtalic anhydride, methylene diphenol diisocyanate, ammonium hexachloroplatinate, trimellitic anhydride, hexamethylen diisocyanate, maleic anhydride and toluendiisocyanate.
- the non-sensitizers were chlorobenzene, zinc sulphate, 4-aminobenzoic acid, methyl salicylate, ethyl vanillin, isopropanol, dimethyl formamide, 1-butanol, potassium permanganate, propylene glycol and tween 80 (Table 2). All chemicals were from Sigma-Aldrich, St. Louis, MO, USA. Compounds were dissolved in either dimethyl sulfoxide (DMSO) or distilled water. Prior to stimulations, the cytotoxicity of all compounds was monitored, using propidium iodide (PI) (BD Biosciences, San Diego, CA) using protocol provided by the manufacturer. The relative viability of stimulated cells was calculated as: fraction of viable stimulated cells
- the human myeloid leukemia-derived cell line MUTZ-3 (DSMZ, Braunschweig, Germany) was maintained in a-MEM (Thermo Scientific Hyclone, Logan, UT) supplemented with 20% (volume/volume) fetal calf serum (Invitrogen, Carlsbad, CA) and 40 ng/ml rhGM-CSF (Bayer HealthCare Pharmaceuticals, Seattle, WA), as described (Johansson H, Lindstedt M, Albrekt AS, Borrebaeck CA: A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests.
- FACSDiva software was used for data acquisition with FACSCanto II instrument (BD Bioscience). 10,000 events were acquired and gates were set based on light scatter properties to exclude debris and nonviable cells. Further data analysis was performed using FCS Express V3 (De Novo Software, Los Angeles, CA).
- Phenotypic analysis chemical exposure, cell harvest and RNA isolation
- MUTZ-3 The maintenance and chemical stimulation of MUTZ-3 and all subsequent isolation of RNA and preparation of cDNA was performed as previously described (Johansson H, Albrekt AS, Borrebaeck CAK, Lindstedt M (2012) The GARD assay for assessment of chemical skin sensitizers. Toxicol in Vitro).
- a phenotypic control of MUTZ- 3 was performed prior to chemical stimulation.
- Stimulated cells were harvested and RNA was isolated.
- a control of the maturity state of the cells was performed by flow cytometric analysis of CD86.
- Preparation of cDNA and hybridization, washing and scanning of the Human Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA, USA) was performed, according to standardized protocols provided by the manufacturer (Affymetrix).
- the predictive performance of the GRPS was estimated using an external dataset consisting of negative chemical stimulations, as well as a method for cross-validation based on Support Vector Machines (SVM) (Noble WS (2006) What is a support vector machine? Nat Biotechnol 24: 1565-1567), as described (Johansson et al., 2011 , supra.).
- SVM Support Vector Machines
- the biological relevance of the GRPS was explored using Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, Inc. Mountain View, USA), by performing a 'Core Analysis'.
- the top 1029 genes were used as IPA input along with fold change values.
- Biological relevance was established by exploring the Canonical Pathways associated with input molecules.
- the array data has been uploaded to ArrayExpress (http://www.ebi.ac.uk arrayexpress/) with accession number E-MEXP-3773. Interrogation of the method for identification of the Prediction Signature
- the data set was divided into a training set and a test set, consisting of 70% and 30%, of the chemical compounds, respectively. The division was performed randomly, while maintaining the proportions of sensitizers and non-sensitizers in each subset at the same ratio as in the complete data set.
- a test biomarker signature was identified in the training set, using ANOVA filtering and backward elimination, as described above. This test signature was used to train a Support Vector Machine (SVM) (Noble WS: What is a support vector machine? Nat Biotechnol 2006, 24(12): 1565-1567), using the training set, which was thereafter applied to predict the samples of the test set.
- SVM Support Vector Machine
- ROC AUC Receiver Operating Characteristic
- mRNA from MUTZ-3 was collected for transcriptional profiling.
- the stimulations included 9 different chemical respiratory sensitizers and 11 different non-sensitizers, all sampled in biological triplicates except for 4-aminobenzoic acid, which was sampled in 6 replicates due to internal controls, and potassium permanganate, which was sampled in only 2 replicates due to a faulty array.
- 4-aminobenzoic acid which was sampled in 6 replicates due to internal controls
- potassium permanganate which was sampled in only 2 replicates due to a faulty array.
- DMSO and distilled water was sampled in 6 replicates each, as vehicle controls. Summarized, the dataset ready for analysis consisted of 74 arrays, each with measurements of 29141 transcripts.
- the first step of analysis involved a p-value filtering of the genes according to their ability to separate respiratory sensitizers from non-sensitizers, as determined by an ANOVA comparing the two groups.
- approximately 1000 genes is an appropriate amount of potential predictors to use as an input in an algorithm for backward elimination ( Johansson H, Lindstedt M, Albrekt AS, Borrebaeck CA: A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics 2011 , 12:399.).
- Using a p-value cutoff at 0.0067 (FDR 19%) 1029 genes were identified.
- the backward elimination algorithm was applied, removing the predictor that contributes the least information in an iterative manner.
- a local minimum in Kullbach-Liebler Divergence (KLD) was observed when 727 predictors was eliminated (figure 1).
- the remaining 302 genes are collectively termed the "GARD Respiratory Prediction Signature", and their ability to differentiate between respiratory chemical sensitizers and non- sensitizers are illustrated in Figure 2.
- SVM Support Vector Machine
- the trained SVM was then used to classify each sample in the remaining 30% of the data, i.e. the test set, as either a respiratory sensitizer or a non-sensitizer.
- the performance of the classifications was evaluated with the area under the Receiver Operating Characteristic (ROC AUC).
- ROC AUC Receiver Operating Characteristic
- This entire cross-validation was iterated 20 times, each time generating different train and test sets, with each train set yielding different Validation Biomarker Signatures.
- the results of these cross-validations are illustrated in Figure 3.
- the median ROC AUC was found to be 0.84, with a range from 0.66 to 0.96.
- the large variations in predictive performance imply that the random exclusion of 30% of the data greatly affects the composition of the Validation Biomarker Signature.
- the cells Prior to chemical challenge, the cells were quality controlled by measuring the cellular expression of common myeloid and dendritic cell markers using flow cytometry. These markers included CD1a, CD14, CD34, CD54, CD80, CD86 and HLA-DR. No deviations from previously published data were found (Johansson et al., 2011 , supra.), ensuring that unstimulated cells were successfully maintained in an immature state. Following chemical stimulation, the general maturity state of the cells was controlled again, as determined by the expression of the co-stimulatory marker CD86, with results presented in Figure 4.
- CD86 Upregulation of CD86 was evident after a number of chemical stimulations, however, due to large standard deviations, only glutaraldehyde and hexamethylen diisocyanate resulted in statistically significant upregulation of CD86. Furthermore, while not statistically significant, an upregulations of CD86 was also evident after a number of control stimulations. Thus, we concluded that CD86 was an unsuited biomarker for respiratory chemical sensitizers. However, many of the compounds used for stimulations in this study were poorly soluble in cell media, and could not be used in concentrations sufficient to induce cytotoxicity. To this end, the increase of CD86 expression can act as a complementary tool to ensure bioavailability of the chemical stimulations. Analysis of the transcriptional profiles in chemically stimulated MUTZ-3 cells
- mRNA from MUTZ-3 was collected for transcriptional profiling.
- the stimulations included 9 different chemical respiratory sensitizers and 11 different non-sensitizers (negative controls), all analyzed in biological triplicates except for 4-aminobenzoic acid, who was analyzed in 6 replicates due to internal controls, and potassium permanganate, which was analyzed in only 2 replicates due to a faulty array.
- DMSO and distilled water was analyzed in 6 replicates each, as vehicle controls. Summarized, the data set ready for analysis consisted of 74 arrays, each with measurements of 29,141 transcripts.
- the first step of analysis involved a p-value filtering of the genes, according to their ability to discriminate respiratory sensitizers from non-sensitizers, as determined by an ANOVA comparing the two groups. Due to computational limits, approximately 1000 genes is an appropriate amount of potential predictors to use as an input in the algorithm for Backward Elimination. In the present data set, this pre-selection of predictor candidates resulted in 1029 genes, with a p-value of 0.0067 or lower, with a False Discovery Rate (FDR) (Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B 57: 289-300) of 19%.
- FDR False Discovery Rate
- Figure 5C shows the same PCA plot as in Figure 5B, with sensitizers colored according to their mechanistic subdomain, as listed in Table 2.
- Ammonium salts tend to be positioned further away from the cluster of non-sensitizers, indicating the most dissimilarity to non-sensitizers in terms of transcriptional profile.
- diisocyanates and acid anhydrides cluster closely together, leaving no possibility to draw any conclusion of any dissimilarities between these two groups at this point.
- glutaraldehyde has not been assigned to a mechanistic subdomain, although it groups closely with both acid anhydrides and diisocyanates, and these samples are thus denoted "Subdomain unknown" ( Figure 5C).
- the predictive performance of the GRPS was evaluated in two ways. Firstly, an external test set consisting of non-sensitizers was used to confirm their position in a PCA plot, based on the GRPS. Secondly, we used a cross-validation method that randomly divided the data into training and test sets, which then were used to train and evaluate the Support Vector Machine classifications.
- the first method was possible to perform due to the availability of an additional set of control chemicals, run in a previous set of experiments in which GARD was first conceived (Johansson ef a/., 2011 , supra.).
- the compounds in this test set were benzaldehyde, chlorobenzene, diethyl phtalate, glycerol, lactic acid, octanoic acid, phenol, salicylic acid and sodium dodecyl sulphate, all sampled in biological triplicates.
- the test set contained nine samples of DMSO and unstimulated controls respectively.
- Figure 6A shows the same PCA plot as Figure 5B, in which the test set has been mapped based on the transcriptional profile of the samples, while not being allowed to influence the principal components. All samples of the test set are correctly grouped together with non-sensitizers of the train set. The lack of respiratory sensitizers in this test set was due to our reluctance to set any of these samples aside, when performing the analysis used to establish the GRPS. Any samples included in this analysis are inappropriate to include in a test set due to the risk of over fitting.
- the trained SVM was then used to classify each sample in the remaining 30% of the data, i.e. the test data set, as either a respiratory sensitizer or a non- sensitizer.
- the performance of the classifications was evaluated with the area under the Receiver Operating Characteristic (ROC AUC).
- ROC AUC Receiver Operating Characteristic
- This entire cross-validation was iterated 20 times, each time generating different training and test sets, with each training set yielding different Validation Biomarker Signatures.
- the results of these cross-validations are illustrated in Figure 6B-C.
- the median ROC AUC was found to be 0.84, with a range from 0.66 to 0.96.
- the Validation Call Frequency (VCF) for each gene in the GRPS is listed in Table 1.
- the VCF describes the frequency by which a certain gene has been included in any of the 20 Validation Biomarker Signatures, thus providing a second measurement by which the predictors can be ranked.
- IPA Ingenuity Pathway Analysis
- TREM1 signaling altered T cell and B cell signaling in rheumatoid arthritis
- communication between adaptive and innate immune cells B cell development, aryl hydrocarbon receptor signaling, dendritic cell maturation, CD28 signaling in T-helper cells, lipid antigen presentation by CD1 , cytotoxic T cell mediated apoptosis of target cells and autoimmune thyroid disease signaling.
- CD28 signaling in T-helper cells
- lipid antigen presentation by CD1 lipid antigen presentation by CD1
- cytotoxic T cell mediated apoptosis of target cells and autoimmune thyroid disease signaling.
- central for all of these pathways is the bridge between innate and adaptive immunity, and the engagement of innate immune responses initiated by recognition of foreign substances, leading to dendritic cell maturation.
- GRPS Key aspects of this process that is well monitored by the GRPS include upregulation of innate receptors, such as TLRs and AHR, upregulation of antigen presentation-associated molecules, such as HLA and CD1 , upregulation of co-stimulatory molecules, such as CD86 and CD40, and upregulation of proinflammatory effector molecules, such as IL-8 and IL-1 B.
- innate receptors such as TLRs and AHR
- antigen presentation-associated molecules such as HLA and CD1
- co-stimulatory molecules such as CD86 and CD40
- proinflammatory effector molecules such as IL-8 and IL-1 B.
- GARD cell-based in vitro test method for skin sensitizers
- the assay relies on the transcriptional profiling of MUTZ-3 cells following compound stimulation, using a predefined biomarker signature as readout. As measurements of these biomarkers are based on expression array technology, great opportunities exist to broaden the applicability domain of this assay.
- GARD Respiratory Prediction Signature a separate biomarker signature termed GARD Respiratory Prediction Signature (GRPS).
- the GRPS was identified, using a set of reference chemicals known to be either respiratory sensitizers or non-sensitizers, and identifying differentially expressed genes in these two groups by an ANOVA p-value filtering followed by a feature selection algorithm for Backward Elimination. The intended use of the obtained GRPS will thus be in a combined in vitro assay, in which MUTZ-3 cells are stimulated with unknown compounds to be classified.
- the compound can be classified as a skin sensitizer, respiratory sensitizer or a non-sensitizer. Chemicals that are able to induce both respiratory and skin sensitization will also be specifically classified as such.
- the predictive performance of the assay in classifying respiratory chemical allergens was estimated by two forms of validations. Firstly, an external test set consisting of triplicates of 9 negative stimulations were successfully classified, as shown in Figure 6A. Secondly, a thorough approach of cross-validation was applied, in which 30% of the data was repeatedly excluded at random to form a test set that were later on classified with an SVM model trained on the remaining 70% of the data.
- IgE antibody in allergic sensitization of the respiratory tract to chemicals, and whether there are mechanisms through which such sensitization can be achieved that are independent of IgE antibody (Kimber I, Dearman RJ (2002) Chemical respiratory allergy: role of IgE antibody and relevance of route of exposure. Toxicology 181-182: 311-315).
- IgE antibody levels There are indeed correlations between IgE antibody levels and clinical symptoms for a number of chemical allergens, e.g. for acid anhydrides.
- less than half of the patients that are sensitized to diisocyanates demonstrate specific IgE antibody in serum.
- Figure 1C shows a PCA based on the GRPS genes, with chemicals colored according to mechanistic domain. No apparent difference is detectable between diisocyanates and acid anhydrides in this plot, as these two groups cluster closely together. While this does not resolve the issue of possibly different mechanistic pathways in sensitization in vivo, IgE dependent or IgE independent, it does confirm that these groups of chemicals induce similar transcriptional changes in MUTZ-3. Instead, the most extreme transcriptional changes are induced by ammonium salts, such as ammonium hexachloroplatinate and ammonium persulfate.
- ammonium salts such as ammonium hexachloroplatinate and ammonium persulfate.
- GRPS is capable of accurately classifying allergens from various mechanistic subdomains.
- IPA analysis was performed.
- the top 1029 genes from p-value filtering were used as input in the IPA software, rather than the top 302 genes of the GRPS.
- the IPA output presented in Table 1 lists the canonical signaling pathways with which the top 1029 genes are most significantly associated. A majority of these pathways are mainly driven by a core set of molecules, including CD86, CD40, TLR1, TLR6, various HLA-DR molecules and CD1 molecules.
- respiratory chemical sensitizers induce increased antigen presentation and upregulation of co-stimulatory molecules in MUTZ-3, arguably in response to ligation of various pattern recognition receptors (PRRs) and intracellular oxidative stress, as indicated by the significance of aryl hydrocarbon receptor (AHR) signaling and glutathione metabolism.
- PRRs pattern recognition receptors
- AHR aryl hydrocarbon receptor
- the biologic response in MUTZ-3 to chemical respiratory allergens is dominated by innate immune response signaling pathways that ultimately leads to cell maturation of this dendritic cell model, with enhanced antigen presentation and interaction with other immune cells as the end result.
- novel findings of usage of signaling pathways that has previously been associated with respiratory sensitization to protein allergens shed some light on the biological process leading to sensitization of the respiratory tract in response to chemical allergens.
- the GRPS is indeed relevant in an immunologically mechanistic perspective, and provides measurement of transcripts that monitor the biologic events leading to respiratory sensitization.
- Verstraelen S Nelissen I, Hooyberghs J, Witters H, Schoeters G, et al. (2009) Gene profiles of a human bronchial epithelial cell line after in vitro exposure to respiratory (non-)sensitizing chemicals: identification of discriminating genetic markers and pathway analysis. Toxicology 255: 151-159.
- Johansson H Lindstedt M, Albrekt AS, Borrebaeck CA (2011) A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics 12: 399. 17. Johansson H, Albrekt AS, Borrebaeck CAK, Lindstedt M (2012) The GARD assay for assessment of chemical skin sensitizers. Toxicol in Vitro.
- MUTZ-3 a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood 100: 701-703.
- TXNIP ENST00000369317 7904726 65 0.
- ENST00000386628 7925821 65 1.
- C12orf35 ENST00000312561 7954711 65 2.
- HMGA2 ENST00000393578 7956867 65 3.
- KRT16 ENST00000301653 8015376 65 4.
- GGTLC2 ENST00000215938 8071662 65 5.
- OSBPL11 ENST00000393455 8090277 65.
- FAM71F1 ENST00000315184 8135945 65
- ATP6V1B2 ENST00000276390 8144931 65 9.
- LOC128102 AF252254 7904429 60 0.
- HLA-DQA1 /// HLA- ENST00000383127 8178193 40 DRA
- HACL1 ENST00000321169 8085608 35
- FAM135A ENST00000370479 8120552 35
- MCOLN1 ENST00000394321 8025183 30 188.
- PRKACA ENST00000350356 8034762 30
- NAPRT1 ENST00000340490 8153430 15
- FCGR1A /// FCGR1B ENST00000369384 7905047 10
- GPI ENST00000356487 8027621 5 289.
- LASS6 ENST00000392687 8046086 5
- #The submitted script reads traindata.txt, testdata.txt and predictionsignature.txt, with example files provided.
- subset2Training ⁇ - is.element(groupsTraining , strsplit(group2,",")[[1]])
- subset2Test ⁇ - is.element(groupsTest , strsplit(group2,",")[[li])
- SenSpe ⁇ - SensitivitySpecificity(res,facTest)
- ProteinNames ⁇ - as.character(as.matrix(ProteinNames)[1 ,])
- subsetl ⁇ - is.element(groups , strsplit(group1 ,”,")[[1]])
- subset2 ⁇ - is.element(groups , strsplit(group2,",")[[1]])
- testModels testar alia modeller som finns i 'models' med alia
- SenSpe ⁇ - SensitivitySpecificity(loglikelihoods,fac)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20147033326A KR20150016523A (en) | 2012-04-26 | 2013-04-26 | Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method |
CA2871350A CA2871350A1 (en) | 2012-04-26 | 2013-04-26 | Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method |
US14/396,422 US20150111771A1 (en) | 2012-04-26 | 2013-04-26 | Method for Identifying Agents Capable of Inducing Respiratory Sensitization and Array and Analytical Kits for Use in the Method |
EP13781556.9A EP2841599A4 (en) | 2012-04-26 | 2013-04-26 | Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method. |
CN201380031747.7A CN104685067A (en) | 2012-04-26 | 2013-04-26 | Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method. |
IN2397MUN2014 IN2014MN02397A (en) | 2012-04-26 | 2013-04-26 | |
BR112014026582A BR112014026582A2 (en) | 2012-04-26 | 2013-04-26 | method for identifying agents capable of inducing respiratory and matrix sensitization and analytical kits for use in the method |
HK15111843.9A HK1211059A1 (en) | 2012-04-26 | 2015-12-02 | Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method |
US15/624,955 US20170283874A1 (en) | 2012-04-26 | 2017-06-16 | Analytical Methods and Arrays for Use in the Same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201207297A GB201207297D0 (en) | 2012-04-26 | 2012-04-26 | Analytical methods and arrays for use in the same |
GB1207297.1 | 2012-04-26 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/396,422 A-371-Of-International US20150111771A1 (en) | 2012-04-26 | 2013-04-26 | Method for Identifying Agents Capable of Inducing Respiratory Sensitization and Array and Analytical Kits for Use in the Method |
US15/624,955 Continuation US20170283874A1 (en) | 2012-04-26 | 2017-06-16 | Analytical Methods and Arrays for Use in the Same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013160882A1 true WO2013160882A1 (en) | 2013-10-31 |
Family
ID=46261886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/053321 WO2013160882A1 (en) | 2012-04-26 | 2013-04-26 | Method for identifying agents capable of inducing respiratory sensitization and array and analytical kits for use in the method. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20150111771A1 (en) |
EP (1) | EP2841599A4 (en) |
KR (1) | KR20150016523A (en) |
CN (1) | CN104685067A (en) |
BR (1) | BR112014026582A2 (en) |
CA (1) | CA2871350A1 (en) |
GB (1) | GB201207297D0 (en) |
HK (1) | HK1211059A1 (en) |
IN (1) | IN2014MN02397A (en) |
WO (1) | WO2013160882A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016083604A1 (en) * | 2014-11-28 | 2016-06-02 | Senzagen Ab | Analytical methods and arrays for use in the same |
WO2019057977A1 (en) | 2017-09-25 | 2019-03-28 | Senzagen Ab | Novel cell line and uses thereof |
WO2020141204A2 (en) | 2019-01-03 | 2020-07-09 | Senzagen Ab | Analytical methods and arrays for use in the same |
US11324787B2 (en) | 2017-01-05 | 2022-05-10 | Senzagen Ab | Analytical methods and arrays for use in the same |
WO2023278664A1 (en) * | 2021-07-02 | 2023-01-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating asthma with solute carrier family 27 member 3 (slc27a3) inhibitors |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102402479B1 (en) * | 2016-03-23 | 2022-05-25 | 센자겐 아베 | Analytical methods and arrays for use in the methods |
TWI793151B (en) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN109828113A (en) * | 2017-11-23 | 2019-05-31 | 复旦大学附属肿瘤医院 | Purposes of the PAPSS1 in the preparation of preparation screening interferon alfa liver cancer sensitive group marker |
CN108304912B (en) * | 2017-12-29 | 2020-12-29 | 北京理工大学 | System and method for realizing pulse neural network supervised learning by using inhibition signal |
CR20210001A (en) | 2018-07-10 | 2021-04-19 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
AR116109A1 (en) | 2018-07-10 | 2021-03-31 | Novartis Ag | DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME |
JPWO2021193700A1 (en) * | 2020-03-25 | 2021-09-30 | ||
CN111596067B (en) * | 2020-06-03 | 2021-06-22 | 四川大学华西第二医院 | Application of ZC3H8 in early warning, diagnosis and prognosis evaluation of POP (Point of Presence) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
WO1998037186A1 (en) | 1997-02-18 | 1998-08-27 | Actinova Limited | In vitro peptide or protein expression library |
US5856090A (en) | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
WO2008037806A2 (en) * | 2006-09-29 | 2008-04-03 | Vlaamse Instelling Voor Technologisch Onderzoek (Vito) | Method for determining the allergic potential of a compound |
US20090029868A1 (en) * | 2006-10-31 | 2009-01-29 | Applera Corporation | Expression signature in peripheral blood for detection of aortic aneurysm |
WO2012056236A2 (en) | 2010-10-26 | 2012-05-03 | Senzagen Ab | Analytical methods and arrays for use in the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5250413B2 (en) * | 2005-05-12 | 2013-07-31 | コーポレーション ヌヴォルト インク. | Current sensor |
-
2012
- 2012-04-26 GB GB201207297A patent/GB201207297D0/en not_active Ceased
-
2013
- 2013-04-26 IN IN2397MUN2014 patent/IN2014MN02397A/en unknown
- 2013-04-26 KR KR20147033326A patent/KR20150016523A/en not_active Application Discontinuation
- 2013-04-26 CA CA2871350A patent/CA2871350A1/en not_active Abandoned
- 2013-04-26 CN CN201380031747.7A patent/CN104685067A/en active Pending
- 2013-04-26 US US14/396,422 patent/US20150111771A1/en not_active Abandoned
- 2013-04-26 WO PCT/IB2013/053321 patent/WO2013160882A1/en active Application Filing
- 2013-04-26 BR BR112014026582A patent/BR112014026582A2/en not_active IP Right Cessation
- 2013-04-26 EP EP13781556.9A patent/EP2841599A4/en not_active Withdrawn
-
2015
- 2015-12-02 HK HK15111843.9A patent/HK1211059A1/en unknown
-
2017
- 2017-06-16 US US15/624,955 patent/US20170283874A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
US5856090A (en) | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
WO1998037186A1 (en) | 1997-02-18 | 1998-08-27 | Actinova Limited | In vitro peptide or protein expression library |
WO2008037806A2 (en) * | 2006-09-29 | 2008-04-03 | Vlaamse Instelling Voor Technologisch Onderzoek (Vito) | Method for determining the allergic potential of a compound |
US20090029868A1 (en) * | 2006-10-31 | 2009-01-29 | Applera Corporation | Expression signature in peripheral blood for detection of aortic aneurysm |
WO2012056236A2 (en) | 2010-10-26 | 2012-05-03 | Senzagen Ab | Analytical methods and arrays for use in the same |
Non-Patent Citations (39)
Title |
---|
"J-F Chatal", 1989, CRC PRESS, article "Monoclonal Antibodies in Immunoscintigraphy" |
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 |
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 |
BURGES, DATA MINING AND KNOWLEDGE DISCOVERY, vol. 2, 1998, pages 121 - 167 |
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
COLLETT ET AL., METHODS, vol. 37, 2005, pages 4 - 15 |
DAUGHERTY ET AL., PROTEIN ENG, vol. 11, no. 9, 1998, pages 825 - 32 |
DAUGHERTY ET AL., PROTEIN ENG, vol. 12, no. 7, 1999, pages 613 - 21 |
FRAKER ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 80, 1978, pages 49 - 57 |
GALVAO DOS SANTOS G ET AL.: "Progress on the development of human in vitro dendritic cell based assays for assessment of the sensitizing potential of a compound", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 236, 2009, pages 372 - 382, XP026035311 * |
GUNNERIUSSON ET AL., APPL ENVIRON MICROBIOL, vol. 65, no. 9, 1999, pages 4134 - 40 |
H ZOLA: "Monoclonal Antibodies: A manual of techniques", 1988, CRC PRESS |
HANES; PLUCKTHUN, PROC NATL ACAD SCI USA, vol. 94, no. 10, 1997, pages 4937 - 42 |
HE; TAUSSIG, NUCLEIC ACIDS RES, vol. 25, no. 24, 1997, pages 5132 - 4 |
HOLDEN NJ ET AL.: "Dendritic cells from control but not atopic donors respond to contact and respiratory sensitizer treatment in vitro with different cytokine production and altered stimulatory capacity", CLINICAL AND EXPERIMENTAL ALLERGY, vol. 38, 2008, pages 1148 - 1159, XP055174917 * |
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 |
J G R HURRELL: "Monoclonal Hybridoma Antibodies: Techniques and applications", 1982, CRC PRESS |
JENKINS, R.E.; PENNINGTON, S.R., PROTEOMICS, vol. 2, 2001, pages 13 - 29 |
KENAN ET AL., METHODS MOL BIOL, vol. 118, 1999, pages 217 - 31 |
KIEKE ET AL., PROC NATL ACAD SCI USA, vol. 96, no. 10, pages 5651 - 6 |
LAL ET AL., DRUG DISCOV TODAY, vol. 15, no. 7, 2002, pages 143 - 9 |
LALKO JF; KIMBER I; DEARMAN RJ; GERBERICK GF; SARLO K ET AL.: "Chemical reactivity measurements: potential for characterization of respiratory chemical allergens", TOXICOL IN VITRO, vol. 25, 2011, pages 433 - 445, XP028132826, DOI: doi:10.1016/j.tiv.2010.11.007 |
LARSSON K; LINDSTEDT M; BORREBAECK CAK: "Functional and transcriptional profiling of MUTZ-3. A myeloid cell line acting as a model for dendritic cells", IMMUNOLOGY, vol. 117, no. 2, February 2006 (2006-02-01), pages 156 - 66 |
MARKS ET AL., J MOL BIOL, vol. 222, no. 3, pages 581 - 97 |
MASTERSON, A. J.; C. C. SOMBROEK; T. D. DE GRUIJL; Y. M. GRAUS; H. J. VAN DER VLIET; S. M. LOUGHEED; A. J. VAN DEN EERTWEGH; H. M.: "MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors", BLOOD, vol. 100, 2002, pages 701 - 703, XP002217763, DOI: doi:10.1182/blood.V100.2.701 |
MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
NEMOTO ET AL., FEBS LETT, vol. 414, no. 2, 1997, pages 405 - 8 |
SANTEGOETS, S. J.; M. W. SCHREURS; A. J. MASTERSON; Y. P. LIU; S. GOLETZ; H. BAUMEISTER; E. W. KUETER; S. M. LOUGHEED; A. J. VAN D: "In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line", CANCER IMMUNOL IMMUNOTHER, vol. 55, 2006, pages 1480 - 1490, XP019422502, DOI: doi:10.1007/s00262-006-0142-x |
SANTI ET AL., J MOL BIOL, vol. 296, no. 2, 2000, pages 497 - 508 |
See also references of EP2841599A4 * |
SHUSTA ET AL., J MOL BIOL, vol. 292, no. 5, 1999, pages 949 - 56 |
SKERRA ET AL., SCIENCE, vol. 240, 1988, pages 1038 |
SMITH, SCIENCE, vol. 228, no. 4705, 1985, pages 1315 - 7 |
STEINMAN ET AL., ANN. REV. IMMUNOL., vol. 9, 1991, pages 271 |
VERSTRAELEN S ET AL.: "Cell types involved in allergic asthma and their use in in vitro models to assess respiratory sensitization", TOXICOLOGY IN VITRO, vol. 22, 2008, pages 1419 - 1431, XP023904599 * |
VERSTRAELEN S; NELISSEN I; HOOYBERGHS J; WITTERS H; SCHOETERS G ET AL.: "Gene profiles of a human alveolar epithelial cell line after in vitro exposure to respiratory (non-)sensitizing chemicals: identification of discriminating genetic markers and pathway analysis", TOXICOL LETT, vol. 185, 2009, pages 16 - 22, XP025884464, DOI: doi:10.1016/j.toxlet.2008.11.017 |
VERSTRAELEN S; NELISSEN I; HOOYBERGHS J; WITTERS H; SCHOETERS G ET AL.: "Gene profiles of a human bronchial epithelial cell line after in vitro exposure to respiratory (non-)sensitizing chemicals: identification of discriminating genetic markers and pathway analysis", TOXICOLOGY, vol. 255, 2009, pages 151 - 159, XP025869202, DOI: doi:10.1016/j.tox.2008.10.014 |
WARD ET AL., NATURE, vol. 341, 1989, pages 544 |
WINTER; MILSTEIN, NATURE, vol. 349, 1991, pages 293 - 299 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016083604A1 (en) * | 2014-11-28 | 2016-06-02 | Senzagen Ab | Analytical methods and arrays for use in the same |
CN107250793A (en) * | 2014-11-28 | 2017-10-13 | 森扎基因有限责任公司 | Analysis method and for array therein |
US11324787B2 (en) | 2017-01-05 | 2022-05-10 | Senzagen Ab | Analytical methods and arrays for use in the same |
WO2019057977A1 (en) | 2017-09-25 | 2019-03-28 | Senzagen Ab | Novel cell line and uses thereof |
US11815509B2 (en) | 2017-09-25 | 2023-11-14 | Senzagen Ab | Cell line and uses thereof |
WO2020141204A2 (en) | 2019-01-03 | 2020-07-09 | Senzagen Ab | Analytical methods and arrays for use in the same |
WO2023278664A1 (en) * | 2021-07-02 | 2023-01-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating asthma with solute carrier family 27 member 3 (slc27a3) inhibitors |
Also Published As
Publication number | Publication date |
---|---|
US20170283874A1 (en) | 2017-10-05 |
CA2871350A1 (en) | 2013-10-31 |
IN2014MN02397A (en) | 2015-08-21 |
EP2841599A1 (en) | 2015-03-04 |
GB201207297D0 (en) | 2012-06-06 |
HK1211059A1 (en) | 2016-05-13 |
BR112014026582A2 (en) | 2017-06-27 |
CN104685067A (en) | 2015-06-03 |
KR20150016523A (en) | 2015-02-12 |
EP2841599A4 (en) | 2015-12-30 |
US20150111771A1 (en) | 2015-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170283874A1 (en) | Analytical Methods and Arrays for Use in the Same | |
US20210189497A1 (en) | Analytical methods and arrays for use in the same | |
US20170285010A1 (en) | Analytical Methods and Arrays for Use in the Same | |
CN109073659A (en) | Apparent gene group analysis discloses the body cell promoter situation of primary gastric adenocarcinomas | |
JP7356415B2 (en) | Novel cell lines and their use | |
ES2913755T3 (en) | Analytical methods and matrices for use therein | |
US20220026411A1 (en) | Analytical methods and arrays for use in the same | |
TW202129009A (en) | Analytical methods and arrays for use in the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13781556 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2871350 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14396422 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013781556 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20147033326 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014026582 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014026582 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141023 |